PFIZER2020-10-012020-12-31in-bse-fin:OneOperatingExpenses01Member PFIZER2020-10-012020-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2020-04-01 2021-03-31 2021-01-27 INR Crores Third quarter Single segment Pharmaceuticals 2020-10-01 2020-12-31 Unaudited Standalone 5934900000.00 145700000.00 6080600000.00 910400000.00 1834200000.00 -618900000.00 941200000.00 38500000.00 272300000.00 900300000.00 4278000000.00 1802600000.00 0.00 1802600000.00 379100000.00 11100000.00 390200000.00 0.00 1412400000.00 0.00 0.00 0.00 0.00 1412400000.00 -22000000.00 1390400000.00 0.00 0.00 457500000.00 10 30.87 30.87 0.00 0.00 30.87 30.87 1.The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on February 05, 2021 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. n n2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. n n3.The financial results for quarter and nine months ended December 31, 2020 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com n n4.The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosure relating to segments is not applicable and accordingly not made. n n5.Pfizer Inc and GSK Plc entered into an agreement in 2018 to merge their consumer healthcare businesses into a single joint venture to form GSK Consumer Healthcare (GSKCH). Subsequent to GSKCH’s deliberations on the Pfizer Consumer Health (PCH) India business, Pfizer Limited has been requested to take appropriate steps to wind down the legacy PCH business in India. This includes 2 brands - Anacin and Anne French. n n Consequently, the Company will be reimbursed actual wind down cost and also a compensation based on the fair value of PCH Products as determined by the independent valuers. The total revenue of the PCH Products for the year ended March 31, 2020 is Rs 26.3 crore. Single segment 2020-04-01 2020-12-31 Unaudited Standalone 17037900000.00 439200000.00 17477100000.00 2473700000.00 4055000000.00 -509000000.00 2662300000.00 115700000.00 821000000.00 2492100000.00 12110800000.00 5366300000.00 0.00 5366300000.00 1445600000.00 -49900000.00 1395700000.00 0.00 3970600000.00 0.00 0.00 0.00 0.00 3970600000.00 -65900000.00 3904700000.00 0.00 0.00 457500000.00 10 86.79 86.79 0.00 0.00 86.79 86.79 Other Expenses 900300000.00 Other Expenses 2492100000.00